Welcome to our dedicated page for Becton Dickinson & Co SEC filings (Ticker: BDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Becton, Dickinson and Company (BD) SEC filings page for ticker BDX provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a New Jersey–incorporated issuer with common stock listed on the New York Stock Exchange, BD files current reports on Form 8-K, annual and quarterly reports, proxy statements and other documents that give investors insight into its financial condition, governance and capital structure.
BD’s recent Form 8-K filings include disclosures on financial results, such as preliminary unaudited revenue and quarterly earnings press releases, as well as corporate events like executive transitions, board appointments and changes in credit facilities. For example, BD has reported the appointment of new directors, the planned transition of its chief financial officer role, and the execution of a third amended and restated revolving credit agreement that provides senior unsecured financing for general corporate purposes. Other 8-K filings describe temporary blackout periods under the BD 401(k) Plan related to a transaction involving Waters Corporation.
Investors can also review BD’s definitive proxy statement on Schedule 14A, which outlines matters for shareholder voting, board composition, executive compensation programs and strategic themes such as the BD2025 and Excellence Unleashed strategies. Debt-related filings, including listings of various series of notes and a Form 25 relating to the removal from listing of 0.034% Notes due 2025, help users understand BD’s capital markets activities. Common stock and several note issues remain registered and listed on the NYSE, as indicated in the filings.
On this page, Stock Titan presents BD’s SEC filings alongside AI-powered summaries that highlight key points from lengthy documents, such as 10-K and 10-Q reports, 8-K event descriptions and proxy materials. Users can quickly identify information about BD’s revolving credit facilities, leverage covenants, executive changes, shareholder meetings and note listings, while still having the option to review the full original filings from EDGAR for detailed analysis.
BDX submission under Rule 144 reports a proposed sale of 75 restricted stock units tied to an 08/20/2025 grant. The filing also lists recent 10b5-1 sales by Michael Feld on 01/26/2026 (75), 12/26/2025 (74) and 12/01/2025 (75), with the amounts shown alongside each trade.
Becton, Dickinson and Company is moving ahead with a large debt tender program, announcing early tender results and pricing for cash offers to repurchase up to $2,000,000,000 aggregate purchase price of multiple senior note series. The Aggregate Offer Cap was increased from $1,600,000,000, and the Offer SubCap for the 4.685% Senior Notes due 2044 was raised to $472,349,000.
By the early tender deadline of February 24, 2026, holders had tendered significant amounts across 15 note series, with demand exceeding the overall cap. As a result, the 3.794% Senior Notes due 2050 will be accepted on a prorated basis, with $262,727,000 principal amount purchased, while several other series are accepted in full. Pricing for each series was set as a fixed spread over designated U.S. Treasury reference securities, producing Total Consideration per $1,000 of principal such as $1,095.99 for the 6.000% Senior Notes due 2039 and $934.25 for the 4.875% Senior Notes due 2044.
The company will settle accepted tenders on February 27, 2026, paying Total Consideration plus accrued and unpaid interest. All notes purchased in the offers will be retired and cancelled, reducing BD’s outstanding debt across these maturities.
Morgan Stanley Smith Barney LLC Executive Financial Services filed a Form 144 notifying of proposed sales of common stock tied to multiple award types and prior open‑market purchases. The filing lists numerous plan‑based vesting events, option exercises and small market purchases dated between 07/06/2021 and 02/20/2026.
The record enumerates specific lot-level entries (performance stock units, restricted stock vesting, option exercise, open market purchases) and quantities such as 1,028, 274, 953, 485, 804, and 1,020 associated with their respective grant or vesting dates.
Becton, Dickinson and Company reported an insider sale. Christopher Delorefice sold 9,366 common shares on 02/18/2026 for $1,708,885.71. The filing lists multiple issuer-side equity award vesting and exercise events dated between 11/26/2024 and 11/26/2025.
Becton Dickinson & Co director Scott L. Bertram reported an open-market sale of common stock. On February 18, 2026, he sold 953 shares at an average price of $182.61 per share. After this transaction, he directly owns 36,763 shares of Becton Dickinson common stock.
BDX filed a Form 144 reporting proposed sales of issuer‑granted common shares. The notice lists multiple restricted stock and performance stock unit vesting rows with share counts and vesting dates, including 11/26/2024 (3,619 shares) and 11/26/2023 (1,099 shares). All rows are described as issuer grants tied to services rendered.
Morgan Stanley Smith Barney LLC Executive Financial Services reported a proposed sale of 953 common shares of BDX under Rule 144, tied to restricted stock vesting under a registered plan with an effective date of 01/27/2026. The filing lists these securities to be sold by the issuer for services rendered and notes securities sold during the past three months.
Becton Dickinson & Co, a 10% owner of Augusta SpinCo Corp, reported a large share distribution. On February 9, 2026, it distributed 284,771,350 shares of Augusta common stock to its own public stockholders for no consideration, on a pro rata basis, under a prior separation agreement.
After this transaction, Becton Dickinson reported owning zero Augusta shares, indicating it no longer held a direct equity stake in Augusta SpinCo Corp.
Becton, Dickinson and Company has launched cash tender offers to purchase up to $1,600,000,000 aggregate purchase price of various outstanding senior notes and debentures. The notes span maturities from 2026 to 2050 and are accepted in a defined priority order, with certain series subject to individual caps.
The 4.669% Senior Notes due 2047 have an offer sub-cap of $1,000,000,000, and the 4.685% Senior Notes due 2044 have an offer sub-cap of $450,000,000. Holders who tender by 5:00 p.m. New York City time on February 24, 2026 are eligible for a $30 per $1,000 early tender payment in addition to the total consideration.
The tender offers expire at 5:00 p.m. New York City time on March 11, 2026, unless extended or earlier terminated. Pricing for each series will be based on a fixed spread over the yield of a specified U.S. Treasury reference security. Settlement is currently expected on February 27, 2026 for early tenders and March 13, 2026 for tenders at expiration, if conditions are satisfied.
Becton Dickinson reported quarterly revenue of $5.252 billion, up slightly from $5.168 billion, with net income rising to $382 million and diluted EPS of $1.34 versus $1.04 a year earlier. Cash from operations was $657 million.
On February 9, 2026, BD spun off its Biosciences and Diagnostic Solutions business and combined it with Waters in a Reverse Morris Trust, receiving a $4 billion cash distribution. BD plans to deploy about $2 billion into an accelerated share repurchase in Q2 2026 and use the remainder mainly for debt repayment.
BD continues large legal and product-liability accruals of about $1.7 billion and recorded an $83 million liability tied to an FDA Warning Letter on its dispensing equipment operations. The company also maintains an active multi‑year share repurchase program and increased authorizations, repurchasing $250 million of stock in the quarter while paying $299 million in dividends.